Heart drugs turn cancer cells into anticancer vaccines

Share this article:

Plant-based drugs primarily used in the treatment of heart failure and arrhythmias have now been found to exert anticancer effects by helping to destroy tumor cells and converting them into a vaccine against remaining cancer cells.

The agents, cardiac glycosides, appear to be exceptionally efficient at inducing “pre-mortem” stress responses in cancer cells, making the cells more vulnerable to the effects of chemotherapy. Moreover, once those cells succumb to treatment, they become vaccines that keep residual tumor cells under control.

As investigators Laurie Menger of Institut Gustave Roussy in Villejuif, France, and colleagues explained in their report in Science Translational Medicine (2012;4[143]:143ra99), some successful chemotherapeutics, particularly anthracyclines and oxaliplatin, induce a type of cell stress and cell death that is immunogenic. The process involved converts the dying cancer cells into a vaccine that stimulates antitumor immune responses.

Menger's group noted that retrospective clinical analysis revealed the heart drug digoxin, a cardiac glycoside, to have a positive impact on overall survival in persons with breast, colorectal, head and neck, or liver cancer when administered during chemotherapy. In the current study, the investigators used fluorescence microscopy to identify cardiac glycosides as effective triggers of immunogenic cell death, and to demonstrate how a combination of chemotherapy plus cardiac glycosides could vaccinate mice against living cancer cells.

The researchers plan to test cardiac glycosides in patients with head and neck cancer.

Share this article:
You must be a registered member of ONA to post a comment.

Next Article in Web Exclusives

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Screening for Lynch syndrome improves health outcomes at an acceptable cost

Screening families of patients with colorectal cancer for a genetic condition would reduce their risk of developing related cancers, new research has determined.

Outcomes in nonsquamous lung cancer comparable with docetaxel or pemetrexed

The first direct comparison of treating nonsquamous lung cancer with either pemetrexed or docetaxel in addition to cisplatin has shown that the two combinations achieve similar progression-free survival.

JAK inhibitors promising in colorectal cancer

JAK inhibitors have been found to halt tumor growth in colorectal cancer with a certain genetic mutation, according to a new study.